EWTX•benzinga•
Edgewise Therapeutics Announced 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy; Announced Significant Decrease in Levels of Serum Creatine Kinase and Fast Skeletal Muscle Troponin I
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2022 by benzinga